Industry Calls On SFDA To Allow Rx-To-OTC Switch Drugs
This article was originally published in PharmAsia News
Executive Summary
Motivated by concerns that the SFDA may abolish the prescription-to-OTC drug switch mechanism, the industry is renewing calls against such a decision